StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$2.85−0.29 (-9.08%)

Close on Nov 18, 2026Market cap $49.05MP/E –Yield –

Verrica Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Verrica Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$28.38M. For fiscal 2025 it was -$12.19M. The highest annual figure on record is -$4.46M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.19M–
FY2024Dec 31, 2024-$65.92M–
FY2023Dec 31, 2023-$65.76M–
FY2022Dec 31, 2022-$21.30M–
FY2021Dec 31, 2021-$30.91M–
FY2020Dec 31, 2020-$40.18M–
FY2019Dec 31, 2019-$30.08M–
FY2018Dec 31, 2018-$21.88M–
FY2017Dec 31, 2017-$4.46M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$13.10M-967.4%
Q1 FY2026Mar 31, 2026-$9.72M–
Q4 FY2025Dec 31, 2025-$7.19M–
Q3 FY2025Sep 30, 2025$1.63M–
Q2 FY2025Jun 30, 2025$1.51M–
Q1 FY2025Mar 31, 2025-$8.13M–
Q4 FY2024Dec 31, 2024-$11.41M–
Q3 FY2024Sep 30, 2024-$20.70M–
Q2 FY2024Jun 30, 2024-$15.21M–
Q1 FY2024Mar 31, 2024-$18.60M–
Q4 FY2023Dec 31, 2023-$23.14M–
Q3 FY2023Sep 30, 2023-$23.92M-1751.7%
Q2 FY2023Jun 30, 2023-$11.62M–
Q1 FY2023Mar 31, 2023-$7.09M–
Q4 FY2022Dec 31, 2022-$6.21M–
Q3 FY2022Sep 30, 2022$1.45M–
Q2 FY2022Jun 30, 2022-$9.12M–
Q1 FY2022Mar 31, 2022-$7.41M-12450.0%
Q4 FY2021Dec 31, 2021-$8.47M–
Q3 FY2021Sep 30, 2021-$11.77M–
Q2 FY2021Jun 30, 2021-$10.73M–
Q1 FY2021Mar 31, 2021$60.00K–
Q4 FY2020Dec 31, 2020-$12.03M–
Q3 FY2020Sep 30, 2020-$9.64M–
Q2 FY2020Jun 30, 2020-$8.63M–
Q1 FY2020Mar 31, 2020-$9.88M–
Q4 FY2019Dec 31, 2019-$7.99M–
Q3 FY2019Sep 30, 2019-$6.54M–
Q2 FY2019Jun 30, 2019-$7.52M–
Q1 FY2019Mar 31, 2019-$8.03M–
Q4 FY2018Dec 31, 2018-$8.19M–
Q3 FY2018Sep 30, 2018-$6.33M–
Q2 FY2018Jun 30, 2018-$5.47M–
Q1 FY2018Mar 31, 2018-$1.89M–
Q4 FY2017Dec 31, 2017-$1.43M–
Q3 FY2017Sep 30, 2017-$1.36M–
Q2 FY2017Jun 30, 2017-$1.10M–
Q1 FY2017Mar 31, 2017-$570.00K–

More Verrica Pharmaceuticals figures

See a number that looks wrong?